Clinical Trial

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-06-16; most recent amendment 2025-04-17.
Status change: Recruiting → Active, Not Recruiting 2025-03-11
Status change: Not Yet Recruiting → Recruiting 2023-08-08
Trial Details
NCT Number NCT05919537
Lead Sponsor Hummingbird Bioscience
Conditions Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor, Metastatic Solid Tumor
Enrollment 68 participants
Start Date 2023-09-06
Primary Completion 2031-03-01 (estimated)
Study Completion 2031-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-18